We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

89 hedge funds and large institutions have $126M invested in TScan Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

0% more funds holding

Funds holding: 89 → 89 (0)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 16

1.32% less ownership

Funds ownership: 85.9% → 84.59% (-1.3%)

39% less capital invested

Capital invested by funds: $208M → $126M (-$82.1M)

Holders
89
Holders Change
–
Holders Change %
0%
% of All Funds
1.17%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
31
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Checkpoint Capital
California
+$4.22M
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.32M
3
BlackRock
BlackRock
New York
+$1.49M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$661K
5
Citadel Advisors
Citadel Advisors
Florida
+$646K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$5.06M
2
SC
Stempoint Capital
New York
-$4.29M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.08M
4
Marshall Wace
Marshall Wace
United Kingdom
-$549K
5
Jane Street
Jane Street
New York
-$468K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$7K -$45.9K -10,118 -82%
US Bancorp
77
US Bancorp
Minnesota
$6.89K -$10K -2,212 -49%
Mirae Asset Global Investments
78
Mirae Asset Global Investments
South Korea
$5.01K +$7.42K +1,636 New
Fidelity Investments
79
Fidelity Investments
Massachusetts
$4.41K +$4.65K +1,025 +241%
AB
80
Amalgamated Bank
New York
$4K – – –
GFM
81
GF Fund Management
China
$3.13K +$4.67K +1,031 New
SCM
82
Sterling Capital Management
North Carolina
$1.46K +$1.87K +412 +606%
RIL
83
Rothschild Investment LLC
Illinois
$319 +$476 +105 New
SS
84
SBI Securities
Japan
$185 +$276 +61 New
Nisa Investment Advisors
85
Nisa Investment Advisors
Missouri
$182 -$276 -61 -50%
ACA
86
Atlas Capital Advisors
Wyoming
$54 – – –
IA
87
IFP Advisors
Florida
$21 +$32 +7 New
GPP
88
Great Point Partners
Connecticut
– -$5.06M -1,016,375 Closed
SC
89
Stempoint Capital
New York
– -$4.29M -860,951 Closed
Jane Street
90
Jane Street
New York
– -$468K -93,876 Closed
Walleye Capital
91
Walleye Capital
New York
– -$422K -84,699 Closed
ECM
92
ExodusPoint Capital Management
New York
– -$278K -55,845 Closed
Millennium Management
93
Millennium Management
New York
– -$242K -48,672 Closed
MIM
94
MetLife Investment Management
New Jersey
– -$116K -23,363 Closed
XT
95
XTX Topco
Cayman Islands
– -$112K -22,438 Closed
EC
96
EntryPoint Capital
New York
– -$103K -20,620 Closed
Two Sigma Investments
97
Two Sigma Investments
New York
– -$78.4K -15,745 Closed
AQR Capital Management
98
AQR Capital Management
Connecticut
– -$64.3K -12,913 Closed
CIC
99
Cornercap Investment Counsel
Georgia
– -$53.7K -10,788 Closed
CFM
100
Catalyst Funds Management
Australia
– -$15.9K -3,200 Closed
1 2 3
4
5

TCRX Hedge Fund Activity: Q4 2024 in Review

89 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2024, worth a combined $126M — down 39% from $208M a quarter earlier.

Fund positioning in TCRX was balanced in Q4 2024: 16 funds opened new positions, 16 closed out, 31 added to existing stakes and 15 trimmed.

The largest buyer was Checkpoint Capital, adding an estimated $4.22M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.06M sold.

  • 89 institutional investors held TScan Therapeutics (TCRX) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $126M of TScan Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
  • 16 funds opened new TScan Therapeutics positions in Q4 2024 and 16 closed out, a net change of 0 holders.
  • The largest TScan Therapeutics buyer in Q4 2024 was Checkpoint Capital, an estimated $4.22M added.
  • The largest TScan Therapeutics seller in Q4 2024 was Great Point Partners, an estimated $5.06M sold.

Based on aggregated 13F filings for Q4 2024.